VivoSeq
Oncology

Selected Advanced Solid Tumors

0

Pipeline Programs↗

5

Active Trials↗

16

Companies Involved↗

Selected Advanced Solid Tumors is an early-stage landscape with 0 programs across 16 companies. The most active players are Merck & Co., ADC Therapeutics S.A., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalA

ADC Therapeutics S.A.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalRegeneron logo

Regeneron

0 programs

PreclinicalN

Numab Therapeutics AG

0 programs

PreclinicalA

Anza Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Completed15 · 54%
Terminated7 · 25%
Recruiting3 · 11%
Active, not recruiting2 · 7%
Unknown status1 · 4%

Clinical Trials

Trial Activity

28 trials

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06400472·495 enrolled
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Recruiting·AAskGene Pharma, Inc.·Phase 1/2·NCT05867420·594 enrolled
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Recruiting·QQurient Co., Ltd.·Phase 1/2·NCT05394103·130 enrolled
A Study YL201 in Patients With Selected Advanced Solid Tumors
Active, not recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT06057922·990 enrolled
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Active, not recruiting·QQurient Co., Ltd.·Phase 1/2·NCT05438420·120 enrolled
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Completed·XXencor, Inc.·Phase 1·NCT03752398·198 enrolled
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Completed·XXencor, Inc.·Phase 1·NCT03517488·150 enrolled
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Completed·PPharmaMar·Phase 1·NCT01831089·69 enrolled
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 1·NCT04659096·15 enrolled
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Completed·XXencor, Inc.·Phase 1·NCT03849469·78 enrolled
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Completed·GSK logoGSK·Phase 1·NCT02723955·829 enrolled
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
Completed·Novartis logoNovartis·Phase 1·NCT01760525·51 enrolled
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Completed·—·Phase 1·NCT01449058·139 enrolled
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02259114·47 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Completed·AADC Therapeutics S.A.·Phase 1·NCT04972981·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)